Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ
Closed
Aug 28, 2026
Day's Range
3.9652 wk Range
0.4110Overview - GLMD - Galmed Pharmaceuticals Ltd.
Key Statistics
Valuation
Enterprise Value
-11.89M
P/E (Trailing)
‪0.01‬
P/E (Forward)
‪-4.18‬
PEG Ratio
‪-0.00034‬
Price / Book
‪2.03‬
EV / EBITDA
‪2.01‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-33.45%‬
Return on Equity
‪-72.11%‬
Ownership
Shares Outstanding
6.59M
Float
798.29K
Short % of Shares Outstanding
‪0.46%‬
Held by Insiders
‪3.03%‬
Held by Institutions
‪1.89%‬
Price stats
Beta
‪0.68‬
50-Day Avg
‪4.47‬
200-Day Avg
‪5.51‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
1 analysts
Market Cap - GLMD - Galmed Pharmaceuticals Ltd.
Peers - GLMD - Galmed Pharmaceuticals Ltd.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- GLMDNASDAQGalmed Pharmaceuticals Ltd.4.33MMarket Cap+69.51%52-week change0.02P/E (Trailing)‪0.00%‬Profit Margin
- ARGXNASDAQargenx SE American Depositary Receipt64.24BMarket Cap+25.70%52-week change40.24P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.35.60BMarket Cap-70.99%52-week change45.79P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE26.05BMarket Cap-8.41%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S17.75BMarket Cap+23.94%52-week change20.58P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma, Inc.14.63BMarket Cap+27.46%52-week change-19.80P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.12.87BMarket Cap+15.26%52-week change179.54P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - GLMD - Galmed Pharmaceuticals Ltd.
About
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutic solutions in the healthcare industry, particularly focusing on liver diseases. Its primary aim is to address the unmet medical needs in the field of liver and metabolic…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
